Savas Ozsu, Neslihan Ozcelik, M. Halil Ozturk, Tevfik Ozlu
European Respiratory Journal 2013 42: P2609; DOI:
Pulmonary thromboembolism(PTE) is a significant cause of morbidity and mortality. Although anticoagulation remains the primary therapy for venous thromboembolism, vena caval filters are an important alternative when anticoagulants are contraindicated. In these condition, vena caval filters(VCF) have been considered an effective alternative form of therapy for PTE. We retrospectively analyzed the records of all patientswith PTE who were diagnosed between 2008 and 2012. Spiral chest computed tomography pulmonary angiography was confirmed diagnosis of acute PTE.
The average age of the patients was 65.4± 15.7 years, and 15 (60%) were females.
Risk factors for the development PE of were;various causes of immobilization (60% ), malignancy (24%) and hereditary thrombophilia (16%). As a result, VCF was placement in 25(4%) of 624 patients with the diagnosis of pulmonary embolism. Indications for filter respectively; 56% the development of bleeding under treatment, 24% although effective treatment the development of recurrent deep vein thrombosis and / or pulmonary embolism, 16% re-embolism (no under treatment), 4% trombocytopenia was occurred under treatment. The average time after installing vena cava filter was 820±707 days. With polyclinic visits and telephone follow-up was determined that 7 (28%) patients were died (3 patient malignancy, 2 patients cardiac failure, 1 patients COPD and 1 patient PTE). The treatment continued with warfarin in 3 patient and molecular weight heparin in 6 patients with VCF. There were no re-embolism and complications in these patients who followed up with VCF. Only one patient was removed filter.Coclusion,we found that long-term safety and efficacy of filters.